Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for Neurodegeneration
- First Online:
- Cite this article as:
- Galetta, K.M., Calabresi, P.A., Frohman, E.M. et al. Neurotherapeutics (2011) 8: 117. doi:10.1007/s13311-010-0005-1
- 1.1k Views
Axonal and neuronal degeneration are important features of multiple sclerosis (MS) and other neurologic disorders that affect the anterior visual pathway. Optical coherence tomography (OCT) is a non-invasive technique that allows imaging of the retinal nerve fiber layer (RNFL), a structure which is principally composed of ganglion cell axons that form the optic nerves, chiasm, and optic tracts. Since retinal axons are nonmyelinated until they penetrate the lamina cribrosa, the RNFL is an ideal structure (no other central nervous system tract has this unique arrangement) for visualizing the processes of neurodegeneration, neuroprotection and, potentially, even neuro-repair. OCT is capable of providing high-resolution reconstructions of retinal anatomy in a rapid and reproducible fashion and permits objective analysis of the RNFL (axons) as well as ganglion cells and other neurons in the macula. In a systematic OCT examination of multiple sclerosis (MS) patients, RNFL thickness and macular volumes are reduced when compared to disease-free controls. Conspicuously, these changes, which signify disorganization of retinal structural architecture, occur over time even in the absence of a history of acute demyelinating optic neuritis. RNFL axonal loss in MS is most severe in those eyes with a corresponding reduction in low-contrast letter acuity (a sensitive vision test involving the perception of gray letters on a white background) and in those patients who exhibit the greatest magnitude of brain atrophy, as measured by validated magnetic resonance imaging techniques. These unique structure–function correlations make the anterior visual pathway an ideal model for investigating the effects of standard and novel therapies that target axonal and neuronal degeneration. We provide an overview of the physics of OCT, its unique properties as a non-invasive imaging technique, and its potential applications toward understanding mechanisms of brain tissue injury in MS, other optic neuropathies, and neurologic disorders.
Key WordsOptical coherence tomographyretinaoptic nervemultiple sclerosisvision
This review describes a number of advancements in the development of OCT as a novel technology that enables objective analysis of the processes of neurodegeneration within a highly discrete and eloquent central nervous system structure—the retina. OCT enables investigators to rapidly and reproducibly evaluate the structural composition of the retina. Ultimately, OCT could substantially increase our understanding of the mechanisms of tissue injury in MS, be used to identify new therapeutic strategies focused on neuroprotection of central axonal and neuronal structures, and also enable the detection and monitoring of the processes of neurorestoration, a treatment goal not yet within the capability of the neurologist [23–28].
FEATURES AND ADVANTAGES OF OCT IMAGING
Features and Advantages of Optical Coherence Tomography Imaging
1. Optical analog of ultrasound
2. Generates cross-sectional images measuring back-reflected echoes of light
3. Interferometric methods used to detect echoes since times are too fast for direct detection
4. Current technology has 8–10 μm resolution; new technology has 5–7 μm resolution
Imaging metrics (current technology)
1. Average retinal nerve fiber layer (RNFL thickness)
2. Quadrant and clockface sector analyses
3. Total macular volumes
4. Quadrant assessment of parafoveal areas
5. Inferior and superior RNFL are thickest [double hump waveform on temporal–superior–nasal–inferior–temporal (TSNIT) analyses]
Imaging metrics (new technology)
1. RNFL mapping
2. Mapping intraretinal layers in the macula
3. 3D-OCT of optic nerve head topography and internal structure
4. Technology is new and metrics remain to be defined
Biomarker features and validation
1. Correlates with high-contrast and low-contrast visual acuity
2. Pathological distribution predicts visual field changes
3. OCT metrics predict brain atrophy
4. Subtypes of multiple sclerosis predict severity of RNFL thinning
5. Measures of laser polarimetry with variable corneal compensation (GDx-VCC) corroborate OCT evidence of axonal degeneration
1. Testing performance is quick and easy
2. Pupil dilation is typically not required
3. Low coefficient of variation for repeated measures
4. Low interindividual and intra-individual variation
5. Low variability across different centers using the same device
6. Scan quality can be assured with disc centering and adequate signal strength
Retinal imaging technologies such as OCT can rapidly evaluate the integrity of the RNFL and the macula for the purpose of tracking disease progression and, potentially, also neuroprotection. Studies have demonstrated that thinning of the RNFL (assessed by average, quadrant, and clockface sector analyses) and volume reductions in the macula are associated with stereotypic declines in visual functioning, as measured by low-contrast letter acuity and visual field analyses (Table 1) [5–9, 11, 14, 24–28, 31].
MULTIPLE SCLEROSIS AND OPTIC NEURITIS AS SPECIFIC MODELS FOR VISUAL PATHWAY AXONAL LOSS
A direct bedside visualization of the retina and optic nerve was first achieved in 1851 following the introduction of the hand-held ophthalmoscope by Helmholtz . Over a century later, in 1974, Frisén and Hoyt  reported their subjective analysis of thinning of the RNFL (which is principally composed of axons from ganglion cell neurons) in patients with MS, as evaluated with hand-held ophthalmoscopy. This observation was corroborated in a postmortem study that demonstrated atrophy of the RNFL (typically containing about 80% axons and 20% glia) in 35 of 49 eyes of patients with MS . Nevertheless, this study was not sufficiently quantitative to enable a full appreciation of the relationship between vision, RNFL thickness, and the integrity of the approximately 1.2 million axons that make up the optic nerve.
Recent years has seen the emergence of ‘quantitative ophthalmoscopes’ such as Heidelberg Retinal Tomography (HRT), laser polarimetry with variable corneal compensation (GDx-VCC), and OCT, all of which can be used to efficiently and objectively measure changes in structural architecture within the retina [5, 29, 52]. Measures derived from these modalities have been shown to directly and reliably relate to visual function and seem to parallel the pathological changes that occur in the brains of patients with MS.
Recent studies have thus demonstrated that MS and optic neuritis (ON) provide useful clinical models with which to couple clinical measures of visual function with validated and objective structural and physiological correlates of MS [5, 24–28, 36]. The anterior visual system is such a frequent target of the MS disease process that, on postmortem analysis, almost all patients with MS will be found to have characteristic changes in the retina and optic nerve, regardless of whether they have previously experienced acute ON [2, 24–28, 53, 54]. In addition, as many as 30–70% of patients with MS will, in fact, have ON during the course of their disease [55, 56]. These data suggest that the visual system has a very high predilection for developing disease-related disability and could be used effectively to illustrate the histopathology of the disease process in MS.
In contrast with occult optic neuropathy in MS, which is a largely subclinical manifestation of disease in the anterior visual system, most cases of acute ON are associated with pain and visual disturbances, including diminished vision, color desaturation, poor low-contrast acuity and sensitivity, and field abnormalities . ON can, therefore, be evaluated with clinical and neurophysiological techniques, such as patient-reported acuity (high and low contrast) and sensitivity, visual field analysis, and visual evoked responses [55, 56]. Furthermore, in one study, coronal, fat-suppressed, T1-weighted gadolinium-enhanced MRI revealed enhancement in the optic nerve in over 90% of cases of optic neuritis (ON), confirming a breach in the integrity of endothelial tight junctions at the blood–brain barrier . Studies with conventional MRI have shown that the optic nerve area declines subsequent to an event of ON when compared with the unaffected (or at least not acutely affected) eye . Retinal imaging techniques have added greatly to our knowledge of this area, revealing changes in retinal architecture that reflect alterations in visual system physiology and function [5, 24–28].
Visual function has been shown to be directly related to the integrity of retinal anatomy. In particular, abnormalities in this complex structure following ON produce corresponding clinical deficits in patient performance on vision tests . However, since visual function is a measure of both anterior and posterior visual pathways, novel imaging approaches that are specific to the retina and optic nerve may enable more specific quantification of axon injury related to ON .
ROLE FOR OCT IN MODELING AXONAL AND NEURONAL LOSS IN MS
The earliest application of OCT technology to the study of MS was reported by Parisi et al.  in 1999. In this study, which utilized first-generation OCT technology, 14 patients with MS who had completely recovered from a previous event of acute ON were analyzed. The thickness of the RNFL was shown to be reduced by 46% in the affected eyes of the patients with MS versus the control eyes (p < 0.01), and by 28% when affected eyes were compared with the ‘unaffected’ eyes of the same patient (p < 0.01). Even in the supposedly unaffected eyes of the patients, however, there was a 26% reduction in RNFL thickness in comparison to the control eyes (p < 0.01).
In 2005, Trip and colleagues  reported their observations with OCT in 11 patients with MS and 14 patients with clinically isolated syndrome, with all individuals having a history of a single episode of ON. The study was a cross-sectional analysis with follow-up ranging from 1 to 9 years after the ON event. Corroborating the previous findings by Parisi et al.  the investigators found a 33% reduction in RNFL thickness in the eyes of the patients when compared with the eyes of matched controls, and a 27% reduction when the affected and unaffected eyes of the same patient were compared (p < 0.001). Trip et al.  extended the utility of OCT by also showing that the macular volume (a reflection of RGC neuronal integrity) was reduced by 11% in the eyes of patients with a history of ON when compared with control eyes (p < 0.001), and by 9% in the affected versus the unaffected eye of the same patient (p < 0.001).
An important finding of these studies was that the apparently unaffected eyes of patients with MS were in fact significantly abnormal when compared with the eyes of matched control individuals, but were less abnormal than the eye of a patient with a history of ON. This finding indicates that ON signifies accelerated and more severe histopathological consequences on the retina, in contrast to a more insidious and less perceptible change in individuals without a history of an acute syndrome, in whom the disease process probably more closely resembles glaucoma.
As a validation of the axonal basis of OCT metrics in the RNFL, Trip and colleagues  showed that such measures correlated better with visual evoked potential P100 amplitudes (a measure of axonal integrity or function) than with P100 latency (typically a reflection of myelin integrity). It is now generally accepted that disruption of myelin has a direct impact on the function and preservation of axons . During the pathological process, however, these two structural elements can become temporarily uncoupled. The axon cylinder might be intact—albeit vulnerable—for a short period during inflammation and myelin disruption. A demyelinated but intact axon has a number of potential destinies: 1) the axon can be remyelinated if viable adult oligodendrocytes in the vicinity can provide new concentric lamellar internodes, or 2) recovery can also be provided by oligodendrocyte progenitors terminally differentiating into adult process-bearing myelinating cells. Even partial remyelination might be protective.
In 2006, Costello and colleagues  reported that the majority of patients with MS who have ON (about 75%) will sustain 10–40 μm of RNFL loss within a period of only about 3–6 months following the initial inflammatory event. This finding is striking given that the RNFL is only about 110–120 μm thick by the age of 15 years and that most individuals (without a history of glaucoma or macular degeneration) will lose only about 0.017% per year in retinal thickness, which equates to approximately 10–20 μm over a 60-year period . Costello et al.  also provided compelling evidence identifying an injury threshold within the RNFL of about 75 μm; thinning of the RNFL below this level led to a corresponding decay in visual function, as measured by automated perimetry.
The development of validated measures of visual functioning has greatly facilitated the exploration for a structural marker for neurodegeneration in MS. Balcer et al.  and Baier et al.  have utilized performance on low-contrast letter acuity charts to compare retinal structure with visual function in patients with MS who have MS pathology in the anterior visual system. Patients with MS and a history of ON will have lower thickness measures of the RNFL than patients with MS but no prior history of ON, or than individuals without a history of either condition. The fact that the severity of visual loss (as confirmed by performance on automated perimetry or low-contrast letter acuity) is a predictor of abnormal retinal architecture is further evidence that OCT can be used as a noninvasive approach to monitor the course of disease in patients with MS and to detect and monitor the efficacy of new therapies targeting mechanisms that might promote neuroprotective effects on retinal axons and ganglion cell neurons (FIG. 2, Table 1) .
Axonal and neuronal degeneration might be readily expected to be present in eyes with a known history of ON, but in recent studies, researchers utilizing OCT to examine RNFL thickness in heterogeneous MS cohorts have also considered how scores for low-contrast letter acuity might also reflect RNFL thinning in the eyes of patients with MS who do not have a history of ON . Among 90 patients (180 eyes) and 36 MS-free control individuals (72 eyes), the average RNFL thickness was significantly reduced in the eyes of patients with MS. As expected, eyes from patients with a known history of one or more attacks of ON had significantly lower RNFL thickness [85 ± 17 μm (± standard deviation)] than did the eyes of patients with MS who did not have a prior ON history (96 ± 14 μm; p < 0.001). RNFL thickness was also reduced in the eyes of patients with MS without an ON history compared with normal control eyes (105 μm; p = 0.03). With use of normative data included in the OCT 4.0 software (Stratus; Zeiss Humphrey Systems, Dublin, CA) for the OCT 3 Stratus, only 40 (22%) of 180 eyes from patients with MS had ‘abnormal’ average RNFL thickness. In view of the fact that the OCT 4.0 normative database considers the fifth percentile for age to be the cutoff for abnormal values, however, abnormalities in RNFL thickness are likely to be of substantially greater prevalence in the eyes of patients with MS and ON.
Results from this study also suggest that the ‘unaffected’ eyes of patients with a history of ON are at a similar risk for axonal loss as the eyes of patients with MS in general; both MS groups have more axonal loss than age-matched control individuals . Low-contrast letter acuity scores were also found to be significantly correlated with overall average RNFL thickness in the eyes of patients with MS (p < 0.001 by use of generalized estimating equation models accounting for age and adjusting for within-patient, inter-eye correlations); for every one-line change in low-contrast letter acuity score, an average RNFL thickness difference of 4 μm was noted. Average overall RNFL thickness also declined with increasing degrees of overall neurological impairment and disability in the MS cohort, and it was significantly associated with the Expanded Disability Status Scale score and disease duration (p = 0.03).
It has now been shown that an RNFL thickness stratification can be achieved when MS is segregated into its various subtypes (Table 1) [5, 11, 13]. In particular, patients with greater brain atrophy, as measured by validated metrics (such as the brain parenchymal fraction), have a more substantial retinal involvement, as measured by RNFL loss [14, 64]. Thus, the eye would seem to be able to accurately model the mechanisms of neurodegeneration and could even be used to detect and monitor neuroprotection in MS. Specifically, OCT can be utilized to measure the integrity of both neurons and their axonal projections within the retina. Further, the severity of retinal damage directly correlates with visual dysfunction clinically, and with both the severity of MS-related brain pathology (i.e., atrophy) and MS clinical subtype designations (as stratified by disease progression status; Table 1) .
While prior studies have emphasized the association between worse visual function and reductions in OCT-measured RNFL thickness  and macular volume  at a single time point, longitudinal studies have also demonstrated that thinning of the RNFL occurs over time in MS, even among eyes with no history of acute ON . Patients at three academic centers underwent OCT-3 (Stratus) measurement of RNFL thickness at 6-month intervals during a mean follow-up of 18 months. Vision was assessed using low-contrast letter acuity (2.5%, 1.25% contrast) and high-contrast visual acuity. Among 593 eyes of 299 MS patients (≥6 months follow-up), eyes with visual loss showed greater RNFL thinning than eyes with stable vision (low-contrast acuity, 2.5%, p < 0.001; visual acuity, p = 0.005). RNFL thinning increased over time, with average losses of 2.9 μm at 2–3 years and 6.1 μm at 3–4.5 years (p < 0.001 vs 0.5-1-year follow-up interval). These patterns were observed for eyes with or without a prior history of ON. Proportions of eyes with RNFL loss greater than test–retest variability (≥6.6 μm) increased from 11% at 0–1 year to 44% at 3–4.5 years (p < 0.001). This study thereby provides compelling evidence that progressive RNFL thinning occurs as a function of time in MS, even in the absence of a history of ON, and is associated with clinically significant visual loss. These findings are consistent with sub-clinical axonal loss in the anterior visual pathway in MS and support the use of OCT and low-contrast acuity as methods to evaluate the effectiveness of putative neuroprotection protocols .
Reproducibility is an important aspect of longitudinal investigations involving OCT technologies, including clinical trials and observational studies. Previous work by Cettomai et al.  showed good levels of inter-rater and test–retest reliability for OCT 3 (Stratus) measurements of RNFL thickness in patients with MS and disease-free controls. A more recent study, however, demonstrated that high-resolution Fourier domain OCT techniques afford an even greater degree of reproducibility of RNFL thickness and macular volume assessments . This prospective study of inter-visit, inter-rater, and intra-rater reproducibility was performed using Cirrus high-resolution OCT. Among 58 patients with MS and 32 healthy controls, there was excellent reproducibility of average and quadrantic RNFL thickness values, average macular thickness, and total macular volume; intraclass correlation coefficients ranged from 0.92 to 0.97 for inter-visit, 0.94 to 0.99 for inter-rater, and 0.83 to 0.99 for intra-rater reproducibility. The authors suggested that, in addition to implementing high-resolution Fourier domain technology, the utilization of specific procedures, such as the reading of algorithms and quality control, can serve to optimize the quality of OCT data .
While MS is classically considered to be a disorder involving the white matter of the central nervous system, recent pathologic and MRI studies of brain tissue have confirmed that neuronal apoptosis and gray matter degeneration do occur in MS. The retina has proven to be no exception to these findings, and the results of a recent postmortem analysis of 82 patients demonstrated retinal atrophy with shrunken neurons . In patients with MS, there was a dropout of RGC in 79% of eyes and inner nuclear layer atrophy (amacrine and bipolar cells) in 40% of eyes. The severity of the retinal atrophy was significantly associated with postmortem brain weight, with a trend towards an association with disease duration. This report by Green and colleagues  provides the first description of inner nuclear layer cell loss in MS and supports a role for forthcoming OCT studies that incorporate segmentation technologies to determine the thicknesses of specific retinal layers and structures.
Electrophysiologic measures of the visual pathway, including visual evoked potentials (VEPs), are generally regarded as complementary to clinical measures of function and structural measures of axonal and neuronal integrity. Naismith et al.  systematically evaluated the utility of OCT and VEPs to detect the presence of clinical and subclinical ON and examined the relation of these measures to visual function. This retrospective, cross-sectional study evaluated 65 subjects (n = 96 eyes) with MS (n = 40), clinically isolated syndrome (n = 1), neuromyelitis optica (NMO, n = 20), and idiopathic demyelination (n = 4). Patients had at least one episode of ON ≥6 months prior to enrollment. VEPs detected ON in 81% of patients (32% of subclinical ON in unaffected eyes and 75% of all subclinical ON). In contrast, using their criteria, they found that OCT identified 60% of eyes with ON and less than 20% of subclinically affected eyes. The authors concluded that OCT is ‘less sensitive than VEPs in optic neuritis.’ On the other hand, to the extent that this study focused on patients and eyes with relatively poor vision, there were likely floor effects with regard to OCT-determined RNFL thickness.
THE FUTURE OF RETINAL IMAGING IN MS
The hypothesis that measures of the RNFL are causally related to visual performance has been corroborated in recent experiments by our group utilizing another type of quantitative ophthalmoscope, GDx-VCC (Table 1) . GDx, which is based on the projection of polarized light and its retardation when propagating through a birefringent medium (such as the RNFL), can be used to measure both the thickness and the integrity of the nerve fiber layer . The physical properties of this technology enable the retinal substructure to be examined in order to assess the integrity of axonal microtubules. While it is common to refer to the intensity of the retardation pictured in the GDx-VCC printout as correlating with nerve fiber layer thickness, it is implicit that this is only in normal retinal tissue; one of the strengths of GDx is that it would seem to denote the quantitative distribution of the nerve fiber regardless of thickness due to edema .
Notwithstanding these differences, we have confirmed that OCT and GDx metrics yield very similar findings with respect to visual loss in patients with MS who have ON . Like OCT, GDx produces measures that correlate with performance on low-contrast letter acuity and with changes in visual field; however, GDx can additionally detect abnormalities even when they are highly restricted to a particular distribution.
OCT, however, is also undergoing improvements. The new high-resolution OCT devices, such as the Cirrus OCT, offer automated disc centering and have longitudinal co-registration to minimize scan-to-scan variability. This device also corrects for eye movement, which will reduce retinal slip and image quality degradation. The high image acquisition speeds afforded by the Fourier domain instruments enable the generation of high-definition OCT images with increased numbers of transverse pixels and improved coverage of the retina, as well as the acquisition of 3-dimensional OCT (3D-OCT) data sets. 3D-OCT imaging is especially promising because projection image data can be summed to provide a virtual fundus image, which enables precise and reproducible registration of individual OCT images to fundus features [68, 69]. Taken together, these features promise to improve the reproducibility of RNFL thickness measurements and other morphometric measurements. Furthermore, 3D-OCT data can be processed to generate virtual circumpapillary scans, which can be registered to retinal features during post-processing (FIG. 5). Volumetric 3D-OCT data also provide comprehensive information on the optic disc. RNFL-thickness maps (analogous to retardance maps from the GDx) or topographic maps (similar to those from HRT) can be generated .
Some important issues remain to be addressed. Different OCT instruments have different measurement protocols as well as different data analysis methods, so careful quantitative studies must be performed to compare morphometry results and to establish consistent normative baselines. In addition, questions remain about which protocols or visualization methods are best suited for a given application. The improved visualization and performance of new OCT technology suggests that it will have an increasingly important role in assessing the processes of axonal and neuronal degeneration in neurological disease in general and for MS in particular.
ROLE FOR OCT IN DISTINGUISHING OTHER OPTIC NEUROPATHIES
Clinical Features that Distinguish Acute Demyelinating Optic Neuritis from Non-Arteritic Anterior Ischemic Optic Neuropathy
Acute demyelinating optic neuritis (ON)*
Non-arteritic anterior ischemic optic neuropathy (NAION)
20–50 years; typically women (3:1)
>50 years; men or women
Present in >90%; exacerbated by eye movement; resolves within 1 week
Uncommon (<10%); headache occurs in temporal arteritis
Pattern of visual loss
Progression over hours to days, 7–10 days maximum; unilateral in adult patients; signs of optic neuropathy (visual acuity, color vision, and visual field defects)
Sudden onset, often noted upon awakening; unilateral in adult patients; signs of optic neuropathy (visual acuity, color vision, and visual field defects)
Optic disc appearance
Optic disc swelling in one-third of patients, retrobulbar in remainder; absence of hemorrhages/exudates
Optic disc swelling, sectoral involvement, hemorrhages; fellow eye disc crowded with small or no cup
Visual field defects
Typically central, but may be arcuate (radiate from physiologic blind spot); cecocentral (involve central vision and physiologic blind spot); hemianopic (involve area to right or left of vertical)
Typically altitudinal (involve area above or below horizontal)
Pattern of visual recovery
Begins within 2–4 weeks, generally favorable overall (20/20 or better in 75% with baseline normal vision)
Modest improvement over months in approximately 40% (by 3 lines or more on Snellen chart)
Acute retrobulbar: Normal RNFL
Acute phase: Elevated RNFL, decreased cup to disc ratio in fellow eye
Acute papillitis: Elevated RNFL
Chronic (>3 months): reduced RNFL thickness by 20–40% in majority of patients
Chronic phase: Reduced RNFL in the majority of patients
Non-arteritic anterior ischemic optic neuropathy
The main differential for ON is non-arteritic anterior ischemic optic neuropathy (NAION). There are no specific diagnostic tests for NAION and the diagnosis remains a clinical one. Typically, patients with NAION are older than 50 years, have no pain and, in almost all cases, the affected optic nerve is swollen acutely. Table 2 lists features that distinguish ON from NAION. One important characteristic of NAION is a small or absent cup in the fellow eye. In most OCT studies, NAION patients have smaller optic cups than controls [75–79]. The reduction in cup size appears to represent an anatomical risk factor for the development of NAION. There have been conflicting results regarding the reduction of total disc area in patients with NAION, with some studies showing a decrease in disc area size [79–81]. Variability in these observations may reflect differences in the technology used to measure disc area, with some studies using OCT technology while others used the HRT.
Following the acute injury, patients with NAION may show significant decreases in RNFL thickness in all quadrants, and these findings correlate well with visual field abnormalities [76, 77]. However, other studies have demonstrated a tendency of NAION to involve the superior quadrant of RNFL, particularly in those patients with inferior altitudinal loss [78, 79]. In the acute phase, the thickness of the RNFL can be dramatically increased to nearly double the values seen in the unaffected fellow eye [78, 79]. In one study of patients with NAION, arteritic anterior ischemic optic neuropathy (AAION) and open angle glaucoma, patients with open angle glaucoma had greater cup size and thinning of the neuroretinal rim than those with NAION and AAION. In comparing patients with AAION and NAION and controlling for the degree of visual field loss, patients with AAION had greater cup volume [80, 81].
Patients with severe visual acuity loss (worse than 20/200) have an increased probability of having testing positive for NMO antibody. In fact, the visual prognosis for patients with severe acuity loss is far worse for those who are NMO positive (>60% are 20/200 or less in 1 eye within 5 years) . Patients with NMO usually have a greater degree of RNFL loss than those with ON and control patients. In one study, the average RNFL thickness for eyes of NMO patients was 63 μm compared to 88 μm for ON eyes and 102 μm for controls . Using linear regression analysis, the authors of this study determined that a diagnosis of NMO was associated with a 24-μm greater RNFL loss than that observed for those patients with ON associated with relapsing remitting MS. These findings also correlated well with more severe visual loss in the NMO group. Finally, NMO eyes may have a more diffuse loss of RNFL compared to the temporal (papillomacular bundle) nerve fiber loss that predominates with ON in the setting of relapsing remitting MS.
Leber’s hereditary optic neuropathy
Leber’s optic neuropathy (LHON) is a hereditary optic nerve condition that predominately occurs in young men . The visual loss in LHON is painless, providing an important distinction from demyelinating ON. Visual loss is often severe, and the fellow eye may become involved in a matter of weeks after the initial presentation. The common point mutations associated with LHON include 11778, 14484, and 3460 . The optic nerve may appear elevated (pseudo-swelling), and teleangiectatic vessels may be evident in approximately 50% of patients.
The OCT findings of LHON demonstrate an interesting sequence of RNFL involvement . In a recent study, a significant increase of RNFL thickness was noted in the temporal and inferior quadrants in the presymptomatic state to disease onset. At 3 months, the thickening was more evident in the superior and nasal quadrants, presumably as the temporal and inferior quadrants (responsible for papillomacular function) began to atrophy. At 9 months, all but the nasal quadrants showed significant thinning. The reason why the inferior quadrant may be affected early on is unclear, but structural changes at the lamina cribosa similar to what occurs in glaucoma may be responsible. It is notable that the retinal nerve fiber swelling of the inferior quadrant followed by that of the superior quadrant may take months to evolve. The occurrence of marked acute vision loss with relatively slow changes in the RNFL in a distinct pattern may provide a clue about the pathogenesis of LHON. Other studies have examined unaffected carriers to detect the earliest changes of LHON and to assess those risk factors that might be associated with development of this disorder. In one OCT study, the mean optic disc area was significantly larger in the carriers than in the affected patients, suggesting a protective role for those patients that have large disc areas . In another study, thickening of the temporal fibers was detected in unaffected carriers, suggesting preferential involvement of the papillomacular bundle in subclinical LHON . The visual prognosis of LHON may vary depending on the specific mitochondrial mutation. Seo et al.  found that those patients harboring the 11778 mutation had significantly more RNFL loss than those with the 14484 mutation. This observation appears to correspond with low visual recovery rate associated with the 11778 mutation.
Other inflammatory disorders of the optic nerve
A number of other inflammatory optic neuropathies should be considered when the visual loss is bilateral or associated with hemorrhages, retinal exudates, or uveitis. These include sarcoid, syphilis, Lyme disease, lupus, cat scratch fever, and viral etiologies. In the routine case of demyelinating ON, serological tests are of limited diagnostic value. In patients with atypical or systemic features, serological studies for sarcoid, syphilis, Lyme disease, Sjogren’s disease, toxoplamosis, cat scratch fever, West Nile virus, human immunodeficiency virus infection, and herpes infection should be considered .
Toxic optic neuropathies
Toxic or nutritional optic neuropathies are suggested when there is bilateral, painless, and symmetrical visual loss. The optic nerve head may appear to be normal or atrophic. Classically, toxic or nutritional optic neuropathies are associated with centrocecal scotomas (central scotomas that connect to the normal blind spot). B12 deficiency and ethambutol toxicity are two common causes. The OCT of toxic optic neuropathy usually demonstrates a bilateral and progressive loss of RNFL. We recently noted that patients with copper deficiency may show retinal nerve fiber loss . Since the human diet requires only a trace amount of copper, it may take decades before the changes are noted. We have seen patients with copper deficiency after gastric surgery for ulcerative disease as well as bariatric surgery for morbid obesity.
Compressive and infiltrative optic neuropathies
When visual loss persists beyond several weeks, the possibility of a tumor or infiltrative process should be considered. The presence of optic atrophy at the initial presentation of suspected ON should also raise the possibility of a tumor or a prior sub-clinical episode of ON. Progressive visual loss, optic atrophy, and optic nerve head shunt vessels should suggest the possibility of an optic nerve sheath meningioma or a pituitary region tumor. Bilateral visual loss in a patient with known cancer or suspected cancer raises the possibility of a paraneoplastic process.
The visual outcome following surgical treatment of a pituitary adenoma can be hard to predict. OCT in several small studies has been useful in predicting visual outcome following the treatment of pituitary adenomas [91, 92]. In a study of 19 patients, a greater RNFL thickness prior to treatment increased the probability of visual recovery following treatment (17 surgical and 2 pharmacological treatments). For each increase in RNFL by 1 μm, the odds of complete recovery were multiplied by 1.29 . A strong correlation was found between the initial visual field defect and the mean RNFL thickness. The prognostic value of RNFL thickness was independent from the effects of age and duration of symptoms . These findings suggest that RNFL thinning is the result of RGC cell axonal degeneration and the product of compression of the anterior visual pathway fibers by the underlying chiasmal mass lesion. The permanent damage of the RNFL correlates with the persistence of the visual field defect. However, since the vast majority of patients in this study showed an improved visual field following surgery, the presence of RNFL thinning should not preclude surgical therapy.
Role for OCT in distinguishing retinal disorders
Central serous chorioretinopathy tends to occur in young men who have a type-A personality. The visual loss is acute and painless. There is a retinal detachment in the region of the macula that produces central visual field loss. Classically, there is a break in the retinal pigment epithelium that results in fluid passing into the subretinal space and a retinal detachment. The process can be well documented by OCT . Fluid under the macula may resolve spontaneously and thus mimic the recovery of ON. Other retinal entities usually pose no major problems in the differential diagnosis of ON because they produce such distinctive retinal changes.
Retinal artery occlusion is distinguished by the presence of retinal whitening characteristic of infarction.
Retinal vein occlusion is distinguished by the presence of retinal hemorrhages, which are often peripheral, and dilated retinal veins.
The distinction between glaucomatous optic neuropathy and demyelinating ON is usually not difficult. Patients with glaucoma usually have progressive loss of vision, elevated intraocular pressures, and optic disc cupping. OCT is frequently used to monitor disease progression. The amount of RNFL loss can be variable in patients with glaucoma, with the greatest rates occurring in those with the higher baseline RNFL thickness. As one might expect, the greatest loss of RNFL occurs in the inferior temporal quadrant corresponding to the superior nasal field . However, in patients with angle closure glaucoma, the separation may be more complicated. Patients with angle closure glaucoma present with acute visual loss and pain. These patients have a small anterior chamber, and the affected eye is often red during the acute attack. Occasionally, patients with open angle glaucoma will present with episodic or acute visual loss. Optic nerve head swelling is absent, but there may be a splinter hemorrhage at the optic disc margin.
OCT IN NEUROLOGIC DISEASE
Early visual aberrations in contrast sensitivity, depth, and motion perception are symptomatic of Alzheimer’s disease (AD). Clinical studies of the optic nerve head and RNFL using photographic methods have suggested that optic neuropathies with RNFL abnormalities are characteristic of AD. Iseri et al.  addressed the conflicting evidence on whether AD and the loss of RGC are linked. Their results showed that the peripapillary RNFL thickness in all quadrants in patients with AD was thinner than that in controls (87.7 ± 23.8 vs 113.2 ± 6.8 μm). Total macular volumes and Mini-Mental State Exam scores correlated significantly (r = 0.70, p = 0.006), while no significant difference was found for VEPs. These results suggest that peripapillary RNFL thickness and macular volume are decreased in patients with AD disease and that the macular volume relates to the severity of cognitive impairment because decreases in macular volume were positively correlated with decreases in Mini-Mental State Exam scores.
By comparison to the more advanced AD patients studied by Iseri et al. , Berisha et al.  focused on patients classified as having mild to moderate dementia. This shift in patient population was made in order to determine where the earliest thinning occurs in patients with AD. Their results indicate that retinal damage due to AD may begin in the superior quadrant (92.2 ± 21.6 μm vs 113.6 ± 10.7 μm for controls, p = 0.02), instead of just overall thinning within all four quadrants. These authors found no statistically significant RNFL thinning in the temporal, nasal, or inferior quadrants. These findings also suggest that neuronal degeneration in the retina may be related to field deficits in AD and that narrowing of retinal venous blood column diameter and a reduction in retinal blood flow rate occur in these patients. However, there was no correlation between RNFL thickness and retinal blood flow.
Visual impairment is a commonly exhibited nonmotor feature of Parkinson’s disease (PD). In particular, the loss of foveal vision has been linked to retinopathy in patients with PD. The use of OCT has allowed for a better understanding of morpohological changes in the retinal neurons . Recent studies have shown that while visual acuity testing suggests only minimal affects in best-corrected PD in comparison to controls, PD patients do lose foveal contrast sensitivity to patterns. It is now possible to determine the functional deficit of the neural retina and retinal output of PD patients through the use of electroretinogram and pattern ERG. Within the dopamine-deficient retina, electroretinogram and pattern electroretinogram results suggest a lack of ganglion cell receptive field organization. Furthermore, OCT can be used to quantify morphology changes of retina in patients with PD. RNFL thinning in PD patients has also been reported, although the results are mixed; in addition, this thinning may be more reflective of RGC and other neuronal loss. Bodis-Wollner’s  results indicate that the inner retina is thinned in relatively early PD and that the loss of RNFL in PD is not secondary to increases in intraocular pressure. In addition to the thinning of the ganglion cell layer, results suggest a thinning of the macular region of the inner retina.
Evaluations of the inner retinal layer and outer retinal layer were also made by Hajee et al. . Their results indicate that patients had increased thinning in early PD and that RNFL loss was not the result of intraocular pressures. The outer retinal layer and inner retinal layer thicknesses were both analyzed, and the thickness of the superior inner retinal layer was lower in patients with PD (88.8 ± 11.3 μm) than in control eyes (103.5 ± 24.3 μm, p = 0.01). When compared with healthy eyes, the retinas of PD patients were approximately 15% thinner. While Inzelberg et al.  reported a stronger effect in the inferior peripapillary quadrant, more recent findings suggest that thickness in the superior and inferior macular regions are approximately equal .
Integrative approaches to understanding the visual function of patients with Friedreich ataxia (FRDA) are necessary for better patient care. In particular, although common in patients with mitochondrial disease, optic neuropathy in FRDA patients is not well understood. Using a variety of techniques to assess the visual pathway, Fortuna et al.  evaluated 26 patients with FRDA. All patients showed a reduced RNFL thickness with varying degrees of severity of axonal loss. Visual fields, OCT, and electrophysiology were used in tandem to ascertain the various states of the visual pathway. Fortuna et al.’s study showed a diffuse and progressive pattern of fiber loss, beginning with the periphery and becoming concentrically worse. All patients showed significantly reduced RNFL thickness in all quadrants and on average (76.0 ± 12.0 vs 100.0 ± 8.9 μm; p < 0.0001). Given the wide variability in clinical presentation, the study also addressed two cases in which patients had sudden bilateral loss of vision similar to clinical course of LHON. Uniquely in these cases, these heterozygote patients were the most severely affected with visual loss. Their OCT results showed average RNFL thickness values of 76.0 ± 12.0 μm compared with 100 ± 8.9 μm in healthy controls (p < 0.0001). This study also shows that FRDA has a unique pattern of visual loss and pathological mechanism unlike that of non-syndromic mitochondrial optic neuropathies. However, as illustrated in the case of the two patients who experienced visual loss spontaneously, LHON mimicking can occur within patients with Friedreich’s Ataxia. Thus, within FRDA there is a variation of clinical expression with respect to RGC degeneration to sudden papillomacular RGC loss.
Rapid advancements in OCT technologies have allowed for improved visualization of the retina. High-resolution Fourier domain OCT has allowed for rapid imaging of the retina as well as 3-dimensional imaging and improved volumetric measurements . OCT has now been incorporated into a number of clinical trials for MS, emphasizing the role of the anterior visual pathway as a model for testing new therapies, particularly those involving neuroprotection. The results of studies have suggested that losses of axons and ganglion cells may be correlated with MRI measures that reflect more global aspects of neuronal and axonal degeneration. Additionally, the capacity for OCT to measure both RNFL and macular thickness makes these measures attractive structural markers to help distinguish MS subtypes and understand disease progression. The incorporation of OCT into the study of neurodegenerative disorders will provide new insights into a more global role for this technology in neurologic disease.
This work was supported by the National Multiple Sclerosis Society (RG 4212-A-4; TR 3760-A-3); NIH/ National Eye Institute (R01 EY 019473; K24 EY 018136); the DAD’s Foundation, and the McNeill Foundation. We are grateful to Dr. Steven Galetta for helpful input and expertise regarding this manuscript.